



Website  
[www.alkermes.com](http://www.alkermes.com)

Ticker Symbol  
(NASDAQ) ALKS

Contacts  
Rebecca Peterson  
Vice President, Corporate  
Communications

Voice: 781-609-6378

Blair Jackson  
Vice President, Business  
Development

Voice: 781-609-6594

Corporate Headquarters  
Alkermes, Inc.  
852 Winter Street  
Waltham, MA 02451

Voice: 781-609-6000  
Fax: 781-890-0524

Alkermes, Inc. is a fully integrated biotechnology company that develops medicines designed to yield better outcomes and improve patients' lives. Our products, which use novel molecules and innovative drug technologies, target widespread diseases including central nervous system (CNS) disorders, addiction and diabetes. We approach the drug development process from a patient-centric perspective, beginning with a thorough understanding of the challenges patients face on a day-to-day basis. Our products are designed with patient needs and behaviors in mind, with the goal of ensuring that patients consistently take their medication for long-term treatment success.

We partner with some of the world's leading pharmaceutical companies to collaboratively manufacture and market the medicines we develop, and also work independently to create our own therapies. We have built a wide range of capabilities, including innovative research programs, clinical development, large-scale manufacturing, and a commercial presence in the marketplace.

## Commercial Products

**RISPERDAL® CONSTA®**  
(risperidone) Long-Acting Injection

**Product:** RISPERDAL CONSTA is a long-acting injectable form of Johnson & Johnson's schizophrenia drug, RISPERDAL® (risperidone). Developed utilizing Alkermes' proprietary Medisorb® technology, RISPERDAL CONSTA is administered once every two weeks, rather than daily, for the management of schizophrenia and bipolar disorder.

**Status:** Johnson & Johnson's subsidiary, Janssen, markets RISPERDAL CONSTA worldwide. It is commercialized in more than 60 countries, including the U.S., the UK, Japan and Germany.

**Market Opportunity:** Schizophrenia is a brain disorder that affects 1-2% of the world's population. Until now, extended-release injection formulations of antipsychotics have been available only for older, typical treatments.

**Additional Developments:** In May 2009, the U.S. Food and Drug Administration (FDA) approved RISPERDAL CONSTA for the treatment of bipolar disorder.

For product information, please visit  
[www.risperdalconsta.com](http://www.risperdalconsta.com).

## VIVITROL®

(naltrexone for extended-release injectable suspension)

**Product:** VIVITROL is an injectable formulation of naltrexone, based on Alkermes' unique Medisorb technology. VIVITROL is designed for once-monthly dosing, eliminating the need for patients to make a daily decision about taking their medicine. Alkermes manufactures VIVITROL at its commercial facility in Ohio and markets the product independently in the U.S. with a focused commercial team. In Russia, Janssen-Cilag, an affiliate company of Cilag GmbH International, is responsible for the commercialization of VIVITROL.

**Status:** VIVITROL is commercially available for the treatment of alcohol dependence in the U.S. and Russia.

**Market Opportunity:** Approximately 18 million people in the U.S. are dependent on or abuse alcohol and half of these individuals are alcohol dependent. An estimated 2.6 million people seek treatment for alcohol problems each year.

**Additional Developments:** Alkermes is currently developing VIVITROL for the treatment of opioid dependence.

For product information, please visit [www.vivitrol.com](http://www.vivitrol.com).

## Management Team

### Richard F. Pops

Chairman, President and Chief Executive Officer

### Kathryn L. Biberstein

Senior Vice President and General Counsel

### Dennis J. Bucceri

Vice President  
Regulatory Affairs

### Madeline D. Coffin

Vice President  
Human Resources

### Elliot W. Ehrich, M.D.

Senior Vice President  
Research and Development  
and Chief Medical Officer

### James M. Frates

Senior Vice President  
Chief Financial Officer

### Blair C. Jackson

Vice President, Business  
Development

### Stephen King

Vice President  
Commercial Operations

### Michael J. Landine

Senior Vice President  
Corporate Development

### Rebecca J. Peterson

Vice President, Corporate  
Communications

### Gordon G. Pugh

Senior Vice President and  
Chief Operating Officer



### Alkermes, Inc.

852 Winter Street  
Waltham, MA 02451  
USA

Tel: 781 609-6000

Fax: 781 890-0524

www.alkermes.com

## Clinical Development Programs

Preclinical	Phase I	Phase II	Phase III	Regulatory Review	Approved
RISPERDAL® CONSTA® (Schizophrenia)					
RISPERDAL® CONSTA® (Bipolar Disorder)					
VIVITROL® (Alcohol Dependence)					
VIVITROL® (Opioid Dependence)					
Exenatide Once Weekly (Diabetes)					
ALKS 27 (COPD)					
ALKS 29 (Alcohol Dependence)					
ALKS 33 (Addiction)					
ALKS 37 (OIC)					
ALKS 36 (Pain)					
ALKS 6931 (RA)					

## Development Candidates

In collaboration with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company, we are developing exenatide once weekly, an extended-release formulation that contains the same active ingredient as BYETTA® (exenatide) injection. BYETTA is a first-in-class injectable medication for the treatment of type 2 diabetes that is administered twice-daily.

In addition, we are developing ALKS 27, an inhaled treatment for chronic obstructive pulmonary disease (COPD) that leverages our proprietary AIR® technology to deliver medication using a small, simple inhaler. We are also developing ALKS 33 for the treatment of addiction and other central nervous systems disorders, ALKS 37 for the treatment of opioid-induced constipation and ALKS 36 for the treatment of pain. In collaboration with Acceleron Pharma, Inc., we are applying our Medifusion™ technology to develop ALKS 6931 for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases.

## Proprietary Technologies

### Medisorb® Technology

Alkermes' injectable extended-release drug delivery system, called the Medisorb® technology is clinically proven and currently manufactured at commercial levels. This technology can play an important role for the

treatment of diseases in which the extended-release formulation of a drug may help to improve outcomes.

### AIR® Technology

The AIR pulmonary drug delivery technology offers a unique, proprietary delivery system for optimized drug delivery to the lungs. The inhaler is designed to be small and easy to use, with the ability to effectively deliver consistent doses of medication.

### Medifusion® Technology

Alkermes' proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, is designed to extend the circulating half-life of proteins and peptides in order to create an effective, long-acting injectable medication. Medifusion is able to extend the half-life of proteins and peptides through the combined action of Fc fusion and hyperglycosylation.

## Manufacturing

With its world class commercial manufacturing facility, Alkermes is well-positioned to support the development, launch and commercialization of its product candidates. A 200,000 square foot cGMP manufacturing facility in Wilmington, Ohio, provides commercial scale manufacturing for extended-release products. RISPERDAL CONSTA and VIVITROL are produced at this location.